Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Goodwill (2016 - 2024)

Historic Goodwill for Tg Therapeutics (TGTX) over the last 9 years, with Q1 2024 value amounting to $799000.0.

  • Tg Therapeutics' Goodwill changed 0.0% to $799000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $799000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $799000.0 for FY2023, which is 0.0% changed from last year.
  • As of Q1 2024, Tg Therapeutics' Goodwill stood at $799000.0, which was down 0.0% from $799000.0 recorded in Q4 2023.
  • Tg Therapeutics' 5-year Goodwill high stood at $799000.0 for Q1 2020, and its period low was $799000.0 during Q1 2020.
  • Over the past 5 years, Tg Therapeutics' median Goodwill value was $799000.0 (recorded in 2020), while the average stood at $799000.0.
  • Examining YoY changes over the last 5 years, Tg Therapeutics' Goodwill showed a top increase of 0.0% in 2020 and a maximum decrease of 0.0% in 2020.
  • Tg Therapeutics' Goodwill (Quarter) stood at $799000.0 in 2020, then changed by 0.0% to $799000.0 in 2021, then changed by 0.0% to $799000.0 in 2022, then changed by 0.0% to $799000.0 in 2023, then changed by 0.0% to $799000.0 in 2024.
  • Its Goodwill was $799000.0 in Q1 2024, compared to $799000.0 in Q4 2023 and $799000.0 in Q3 2023.